New York, June 2, 2026, 12:07 EDT
Bluejay Diagnostics shares surged in late-morning Nasdaq trading on Tuesday after the micro-cap diagnostics company announced a U.S. manufacturing partnership for its Symphony sepsis-testing platform. The stock was up about 171% at $5.88 after touching $8.38, with volume above 61 million shares and market value still only about $5.8 million.
Why it matters now is not just the headline. Bluejay is trying to move from clinical development toward a commercial product, and the new partner, Argonaut Manufacturing Services, is meant to help shift more of that work inside the United States and reduce exposure to overseas sourcing and import tariffs. Neil Dey, Bluejay’s chief executive, called it a push for a “scalable and quality-focused operational foundation”; Argonaut CEO Rick Hancock cited support for “differentiated diagnostic technologies.” GlobeNewswire
A filing showed Bluejay signed the Argonaut agreement on May 27. The work covers planning, engineering, sourcing, supply chain management, formulation, filling, finishing, quality-control testing, capital equipment, storage, delivery and distribution for Bluejay’s IL-6 products, with purchase orders to set the terms as work is placed.
IL-6, or interleukin-6, is an inflammation-related protein. Bluejay’s lead product is designed as a near-patient test — meaning it is run close to the patient rather than sent through a full central-lab workflow — for sepsis triage and disease monitoring, with a claimed sample-to-result time of about 20 minutes. The company says the device remains investigational and lacks U.S. regulatory clearance.
The deal lands while Bluejay is pushing its SYMON-II pivotal study, meant to help validate earlier work and support a 510(k) submission. A 510(k) is an FDA premarket filing that seeks clearance by showing a device is substantially equivalent to a legally marketed device. Bluejay said on May 7 it had enrolled roughly 680 patients toward a target of 750 and was advancing cartridge manufacturing work with Sanyoseiko.
Competitive context is not easy for a company this small. Roche sells an Elecsys IL-6 immunoassay for cobas analyzers used with clinical evaluation in critically ill patients, while bioMérieux markets VIDAS B.R.A.H.M.S PCT, a procalcitonin test tied to sepsis-risk and antibiotic decisions. Bluejay’s pitch is speed and placement near the patient, if it can get the product cleared.
But the manufacturing agreement does not remove the central risks. Bluejay’s 10-Q said it depends on raising capital, remaining a going concern and producing product capable of validation; it also said cash resources were expected to fund operations only through the third quarter of 2026 and that more capital would be needed. A delay in cartridge verification, weak clinical data, an FDA setback or a discounted raise could turn Tuesday’s rally into a fast reversal.
For now, investors are treating manufacturing as a milestone. The next proof points are less headline-friendly: purchase orders, completed enrollment, verified cartridges and a credible path to an FDA filing.
